Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Mercaptobenzimidazole SCHEMBL29360590 | 1.00 | ALDH1A1 (1.00) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| 2-Mercaptobenzimidazole SCHEMBL29562524 | 0.97 | ALDH1A1 (0.94) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| 2-Mercaptobenzimidazole SCHEMBL7550230 | 0.87 | ALDH1A1 (0.75) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| SCHEMBL853857 | 0.80 | ALDH1A1 (0.67) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| SCHEMBL2680080 | 0.79 | KMT2A (0.64) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| SCHEMBL7116569 | 0.77 | KDM4E (1.00) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| SCHEMBL1342985 | 0.75 | KDM4E (0.63) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| SCHEMBL29446348 | 0.75 | KDM4E (0.63) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| SCHEMBL30644752 | 0.75 | ALDH1A1 (0.58) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 | |
| SCHEMBL10492852 | 0.74 | MAPT (0.59) | ALDH1A1PSMB8HSD17B10MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 617 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-26 | — | — | US | claimed |
| WO-2025122555-A1 | S1P 1 RECEPTOR AGONISTS AND USES THEREOF | VALO HEALTH, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| CN-111788183-B | Heterocyclic fused phenyl compounds useful for inhibiting TNIK and medical uses thereof | 韩国化学硏究院 | 2024-02-23 | — | — | CN | claimed |
| WO-2023245156-A2 | VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-12-21 | — | — | WO | claimed |
| EP-3749647-B1 | N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-09-27 | — | — | EP | claimed |
| US-20220315523-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-10-06 | — | — | US | claimed |
| US-11447469-B2 | Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-09-20 | — | — | US | claimed |
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | claimed |
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-02-18 | — | — | US | claimed |
| EP-3749647-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2020-12-16 | — | — | EP | claimed |
| EP-0384522-B1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-01-13 | — | — | EP | claimed |
| EP-0316649-B1 | WATER INSOLUBLE AZO COLOURING AGENTS, THEIR PREPARATION AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-22 | — | — | EP | claimed |
| US-5026831-A | Water-insoluble disazo colorants having hetero-bicyclic methylene-active compounds as coupling component | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | claimed |
| EP-0408203-A2 | Heterocyclic thione | ZENECA LIMITED (GB) | 1991-01-16 | — | — | EP | claimed |
| EP-0384522-A1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-08-29 | — | — | EP | claimed |
| US-4551419-A | HIGH PHOTSENSITIVITY AND CONTRAST BY INCLUDING A SULFUR COMPOUND AND A MERCAPTO-CONTAINING AZAINDENE STABILIZER | FUJI PHOTO FILM CO., LTD. (JP) | 1985-11-05 | — | — | US | claimed |
| EP-0014928-B1 | PIPERIDINOPROPYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1982-05-05 | — | — | EP | claimed |
| US-4288442-A | Inhibiting adrenergic β-receptors with piperidinopropyl derivatives | BOEHRINGER MANNHEIM GMBH (DE) | 1981-09-08 | — | — | US | claimed |
| US-4216284-A | NONDIFFUSIBLE SILVER BLEACH INHIBITOR | FUJI PHOTO FILM CO., LTD. (JP) | 1980-08-05 | — | — | US | claimed |
| US-4001020-A | DEVELOPING A SILVER HA1IDE EMULSION IN CONTACT WITH A HETEROCYCLIC THIONE AND A POLYALKYLENE OXIDE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | ALDH1A1 4644/4885PSMB8 1862/4885HSD17B10 3092/4885 |
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | SLC18A2, SLC6A2, SLC6A3 | ALDH1A1 2459/4885PSMB8 3739/4885HSD17B10 824/4885 |
| US-11447469-B2 | Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | ALDH1A1 4644/4885PSMB8 1862/4885HSD17B10 3092/4885 |
| US-20220315523-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | ALDH1A1 1310/4885PSMB8 3652/4885HSD17B10 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.